Free Trial

The Cigna Group (CI) Stock Forecast & Price Target

The Cigna Group logo
$335.60 -0.10 (-0.03%)
Closing price 04/25/2025 03:59 PM Eastern
Extended Trading
$331.34 -4.27 (-1.27%)
As of 04/25/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
17

Based on 19 Wall Street analysts who have issued ratings for The Cigna Group in the last 12 months, the stock has a consensus rating of "Buy." Out of the 19 analysts, 2 have given a hold rating, 15 have given a buy rating, and 2 have given a strong buy rating for CI.

Consensus Price Target

$373.56
11.31% Upside
According to the 19 analysts' twelve-month price targets for The Cigna Group, the average price target is $373.56. The highest price target for CI is $438.00, while the lowest price target for CI is $323.00. The average price target represents a forecasted upside of 11.31% from the current price of $335.60.
Get the Latest News and Ratings for CI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for The Cigna Group and its competitors.

Sign Up

CI Analyst Ratings Over Time

TypeCurrent Forecast
4/28/24 to 4/28/25
1 Month Ago
3/29/24 to 3/29/25
3 Months Ago
1/29/24 to 1/28/25
1 Year Ago
4/29/23 to 4/28/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
15 Buy rating(s)
13 Buy rating(s)
13 Buy rating(s)
10 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$373.56$373.25$395.93$362.14
Forecasted Upside11.31% Upside14.86% Upside30.78% Upside2.16% Upside
Consensus Rating
Buy
Buy
Buy
Moderate Buy

CI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

The Cigna Group Stock vs. The Competition

TypeThe Cigna GroupMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.82
2.54
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside11.31% Upside2,806.58% Upside21.41% Upside
News Sentiment Rating
Positive News

See Recent CI News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/15/2025Robert W. Baird
2 of 5 stars
Michael Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$388.00 ➝ $362.00+10.13%
4/11/2025Truist Financial
2 of 5 stars
David Macdonald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$375.00 ➝ $385.00+17.62%
4/9/2025Guggenheim
2 of 5 stars
Jason Cassorla
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$384.00+23.54%
4/9/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$360.00 ➝ $384.00+22.66%
3/20/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sarah James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$350.00 ➝ $365.00+13.53%
2/6/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Wilkes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$323.00+10.24%
2/4/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Stephen Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$370.00 ➝ $341.00+16.46%
2/3/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kevin Caliendo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$410.00 ➝ $390.00+31.64%
2/3/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jessica Tassan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$394.00 ➝ $348.00+18.13%
1/31/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Ben Hendrix
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$355.00+18.36%
1/31/2025Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
John Ransom
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$415.00 ➝ $360.00+21.26%
1/31/2025Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Wiederhorn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$400.00 ➝ $375.00+26.31%
1/31/2025Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Raj Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$410.00 ➝ $380.00+28.89%
1/31/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Erin Wright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$403.00 ➝ $379.00+34.20%
1/31/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Mok
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$420.00 ➝ $339.00+20.03%
11/4/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$398.00 ➝ $394.00+25.93%
9/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$402.00 ➝ $422.00+16.25%
8/21/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$435.00 ➝ $438.00+27.49%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/17/2023Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
8/4/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$320.00 ➝ $350.00+21.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 05:13 AM ET.


Should I Buy The Cigna Group Stock? CI Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, April 22, 2025. Please send any questions or comments about these The Cigna Group pros and cons to contact@marketbeat.com.

The Cigna Group
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in The Cigna Group:

  • The current stock price is around $335, reflecting a recent increase, which may indicate positive market sentiment and potential for further growth.
  • The Cigna Group has a strong market capitalization of approximately $91 billion, suggesting stability and a solid position in the health services sector.
  • The company recently increased its quarterly dividend to $1.51 per share, representing a yield of about 1.80%, which can provide a steady income stream for investors.
  • Analysts have set optimistic price targets, with some expecting the stock to reach as high as $384, indicating potential upside for investors.
  • The Cigna Group reported a return on equity of 18.61%, showcasing effective management and profitability, which can be attractive to investors looking for strong financial performance.

The Cigna Group
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in The Cigna Group for these reasons:

  • The company recently missed earnings expectations, reporting $6.64 per share against a consensus estimate of $7.84, which may raise concerns about its financial performance.
  • Insider selling has been noted, with significant shares sold recently, which could signal a lack of confidence from those closest to the company.
  • The stock has a relatively high price-to-earnings (P/E) ratio of around 27, which may suggest that it is overvalued compared to its earnings potential.
  • The Cigna Group has a net margin of only 1.39%, indicating that profitability may be under pressure, which could concern investors about future earnings stability.
  • Market volatility and economic uncertainties could impact the health services sector, potentially affecting The Cigna Group's performance and stock price.

CI Forecast - Frequently Asked Questions

According to the research reports of 19 Wall Street equities research analysts, the average twelve-month stock price forecast for The Cigna Group is $373.56, with a high forecast of $438.00 and a low forecast of $323.00.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for The Cigna Group in the last year. There are currently 2 hold ratings, 15 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CI shares.

According to analysts, The Cigna Group's stock has a predicted upside of 11.31% based on their 12-month stock forecasts.

Over the previous 90 days, The Cigna Group's stock had 1 downgrade by analysts.

Analysts like The Cigna Group more than other "medical" companies. The consensus rating for The Cigna Group is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CI compares to other companies.


This page (NYSE:CI) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners